Cancer immunology

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Thursday, November 15, 2018
Medicine, Cancer, Health, RTT, Society for Immunotherapy of Cancer, Oncology, Breast cancer, Cancer immunology, Cancer immunotherapy, Prostate cancer, Immune system

The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to treat cancer.

Key Points: 
  • The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to treat cancer.
  • "We are pleased to make our presentation titled, Combining the immunophenotyping of MDSCs and lymphocytes with artificial intelligence (AI) to predict early stage breast cancer, at the AACR Tumor Immunology and Immunotherapy conference.
  • This data is focused on using our Cchek technology to detect breast cancer in its early stages.
  • We recently presented our latest prostate cancer data at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC), and we look forward to now present our latest breast cancer data at this AACR special conference," added Dr. Kumar.

BioInvent Announces Publication of Data in Leading Cancer Journal Immunity

Retrieved on: 
Tuesday, November 13, 2018
Medicine, Clinical medicine, Health, Immunology, T cells, Regulatory T cell, Immunotherapy, Cancer research, Cancer immunology, Cancer, Lloyd J. Old, Active immunotherapy

Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.

Key Points: 
  • Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.
  • This research is the result of a long-standing collaborative effort between the Southampton Antibody and Vaccine Group, Centre for Cancer Immunology, BioInvent and Cancer Research UK, to promote translational research into effective cancer immunotherapies.
  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.

BioInvent Announces Publication of Data in Leading Cancer Journal Immunity

Retrieved on: 
Tuesday, November 13, 2018
Medicine, Clinical medicine, Health, Immunology, T cells, Regulatory T cell, Immunotherapy, Cancer research, Cancer immunology, Cancer, Lloyd J. Old, Active immunotherapy

Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.

Key Points: 
  • Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.
  • This research is the result of a long-standing collaborative effort between the Southampton Antibody and Vaccine Group, Centre for Cancer Immunology, BioInvent and Cancer Research UK, to promote translational research into effective cancer immunotherapies.
  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.